NEW YORK, August 6, 2026, 05:07 EDT — The U.S. cash markets remained shut, while premarket activity continued.
- At 5:00 EDT, shares were quoted at $361.49, an increase of 0.63%. Just 2,254 shares had changed hands.
- Earlier this year, prosecutors examined allegations related to over $100 million in rejected reimbursements. The present status of that review remains uncertain.
- The consensus analyst price target stood at $359.33, which is nine cents higher than the closing price on Wednesday.
The initial market reaction was muted. Following the Wall Street Journal report, JPMorgan shares rose 0.6%. That indication is constrained by the low premarket trading volume.
The reported minimum reimbursement exceeds $100 million. At the $100 million level, this is 0.59% of net income for the second quarter, excluding notable items. It also represents 86% of the company’s total legal expenses for that quarter.
The muted price reaction is clarified by the first ratio. The second highlights a tougher issue for investors: ongoing expenses related to control. JPMorgan’s valuation barely allows for such costs.
The assessment was prompted by a complaint from Christy Lillie, previously the head of scam-prevention at JPMorgan. She claimed that certain losses were labeled as scams instead of fraud. According to the allegation, this designation made it possible to reject reimbursement requests.
According to the reports, prosecutors and Treasury officials held discussions with Lillie and were given documents. No allegations of wrongdoing have been made by prosecutors. JPMorgan stated: “We believe these claims have no merit.” The bank said its examination uncovered no breaches of law. The Wall Street Journal
The legal difference may be crucial. Regulation E partially bases the definition of an unauthorized transfer on who starts the transaction. The presence of actual authority and whether the consumer gains any benefit are also important. These elements can affect reimbursement results.
This initial assessment refers to $100 million, the minimum cited in the complaint. The amount does not represent a confirmed liability.
| Comparison base | Reported amount | $100 million as a share |
|---|---|---|
| Q2 stated net income | $21.2 billion | 0.47% |
| Q2 net income before significant items | $16.9 billion | 0.59% |
| Q2 overall legal expense | $116 million | 86.2% |
| FY2026 guidance for adjusted expenses | $107.5 billion | 0.09% |
JPMorgan does not include company-wide legal expenses in its adjusted-expense metric. As a result, any such legal charges would fall outside of its $107.5 billion goal.
The earnings base provides significant protection. Second-quarter reported profits were $21.2 billion. Excluding large items, profit came to $16.9 billion, with a return on tangible common equity of 23%. Chief Executive Jamie Dimon described the results as “very strong results in the quarter.” JPMorgan Chase
Market valuations are stricter. JPMorgan’s most recent P/E ratio stood at 17.2, higher than those of two major consumer bank rivals.
| Company | Latest regular price | Market value | P/E ratio |
|---|---|---|---|
| JPMorgan Chase | $359.24 | $977.2 billion | 17.2 |
| Bank of America NYSE:BAC | $63.25 | $461.4 billion | 14.6 |
| Citigroup NYSE:C | $137.64 | $244.4 billion | 17.0 |
| Wells Fargo NYSE:WFC | $89.17 | $274.2 billion | 13.0 |
JPMorgan’s multiple stands roughly 18% higher than the median of its three peers. The stock closed only 1% short of its 52-week peak.
Shares dropped 0.4% during the week ending July 31. From the start of this week through Wednesday, they increased 2.1%. Over the same period, the S&P 500 advanced 3.1%, with JPMorgan trailing the broader market gains.
The rally continues to offer backing. The Dow and S&P 500 hit all-time highs on Tuesday, and over 80% of S&P firms announcing results have surpassed forecasts. Oliver Pursche of Wealthspire Advisors cited “a general sense of optimism.” Reuters
Analysts retain a positive stance, yet price targets are largely unchanged. Of 28 ratings, the consensus is “Moderate Buy,” with 17 analysts bullish and none recommending a sell. Recent analyst calls vary significantly. MarketBeat
| Date | Brokerage and analyst | Recommendation | Target | Implied move from $359.24 |
|---|---|---|---|---|
| Consensus | 28 analysts | Moderate Buy | $359.33 | 0.0% |
| Aug. 3 | UBS Group NYSE:UBS, Erika Najarian | Buy | $400 | +11.3% |
| July 20 | Citigroup, Keith Horowitz | Neutral | $360 | +0.2% |
| July 16 | Bank of America, Ebrahim Poonawala | Buy | $420 | +16.9% |
| July 15 | Royal Bank of Canada NYSE:RY, Gerard Cassidy | Outperform | $370 | +3.0% |
| July 15 | Robert W. Baird, David George | Neutral | $305 | -15.1% |
The average target is just $0.09 higher than where shares finished on Wednesday. Optimistic forecasts depend on sustained earnings momentum. More cautious targets indicate the potential downside if confidence wanes.
Several key macroeconomic reports are due soon. Productivity figures are set for release ahead of Thursday’s market open, with data on payrolls, inflation, and producer prices to follow.
| Date | U.S. release | Time, EDT | Main bank-market sensitivity |
|---|---|---|---|
| Aug. 6 | Q2 productivity and costs, preliminary | 08:30 | Wage and margin dynamics |
| Aug. 7 | Employment data for July | 08:30 | Interest rates, credit strength |
| Aug. 12 | Consumer price index for July | 08:30 | Rate direction, market valuation |
| Aug. 13 | Producer price index for July | 08:30 | Upstream inflation |
Risks continue to exist on both sides. If the review ends with no action, the earnings outlook would remain unchanged. However, if there is a wider redress or anti-money-laundering action, legal and compliance expenses could increase. Both possibilities are currently unconfirmed.
The following update is not the $100 million headline. Investors require more information on the review process, the impacted cases, and any charges beyond current guidance. With shares trading close to record highs and the consensus target unchanged, there is limited room for error.
Related articles: NYSE:BAC
